Absci Corporation

ABSI

US00091E1091

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
3.08 ^USD	+0.98%		+1.99%	-26.67%

10/06	Absci Seeks M&A Opportunity	CI
10/06	Transcript : Absci Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 02:00 PM

Absci Corporation Announces End of Nikhil Goel as Chief Strategy Officer

September 21, 2022 at 02:45 am IST

On September 15, 2022, Absci Corporation and Nikhil Goel, the Company's Chief Strategy Officer, agreed that Mr. Goel's employment with the Company would end effective as of September 20, 2022.

Latest news about Absci Corporation

Absci Seeks M&A Opportunity	10/06	CI
Transcript : Absci Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 02:00 PM	10/06
Certain Restricted Stock Unit of Absci Corporation are subject to a Lock-Up Agreement Ending on 28-MAY-2024.	28/05	CI
Certain Options of Absci Corporation are subject to a Lock-Up Agreement Ending on 28-MAY-2024.	28/05	CI
Certain Common Stock of Absci Corporation are subject to a Lock-Up Agreement Ending on 28-MAY-2024.	28/05	CI
Transcript : Absci Corporation, Q1 2024 Earnings Call, May 14, 2024	14/05
Earnings Flash (ABSI) ABSCI CORPORATION Posts Q1 Revenue $898,000, vs. Street Est of $2.1M	14/05	MT
Absci Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Earnings Flash (ABSI) ABSCI CORPORATION Reports Q4 Revenue $338,000	21/03	MT
Absci Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI
Absci Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03	CI
Scotiabank Starts Absci With Sector Outperform Rating, $13 Price Target	14/03	MT
KeyBanc Raises Price Target on Absci to $8 From $5, Keeps Overweight Rating	04/03	MT
Absci Initiates IND-Enabling Studies for Abs-101, A Potential Best-In-Class Anti-Tl1a Antibody De Novo Designed and Optimized Using Generative Ai	21/02	CI
Transcript : Absci Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 10:30 AM	12/01
HC Wainwright Raises Absci's Price Target to $7 From $4, Buy Rating Kept	09/01	MT
Absci Corporation to Present Preclinical Data for ABS-101, A Potential Best-In-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference	08/01	CI
Absci, PrecisionLife to Develop AI-Enabled Drug Pipeline	21/12	MT
Sector Update: Health Care	21/12	MT
Absci Corporation and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline	20/12	CI
Absci Corporation(NasdaqGS:ABSI) dropped from NASDAQ Biotechnology Index	15/12	CI
Absci Corporation Appoints Menelas Pangalos as Class II Director and Member of Compensation Committee of the Board, Effective January 1, 2024	07/12	CI
KeyBanc Initiates Absci at Overweight With $3 Price Target, Calls Valuation 'Attractive' Given New Drug Programs, Partnerships	05/12	MT
AstraZeneca: AI collaboration with Absci	04/12	CF
Absci Shares Rise 27% After Announcing Collaboration With AstraZeneca	04/12	DJ

Absci Corporation is a generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. It has built an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The Company uses its platform to predict, identify, design, construct, screen, select and scale production of biologic drug candidates for its partners, and learn from the data it generates. Its SoluPro technology is a multiplex synthetic biology approach that overcomes the limitations of highest-throughput automation labs. The Company supports its generative AI designs with its wet lab's high-throughput functional validation capabilities. It reconstructs prevalent immune-response molecules, such as antibodies from disease tissue and identify their corresponding antigens, offering new therapeutic targets.

Sector

Biotechnology & Medical Research

Calendar

03/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Absci Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.08 USD

Average target price

8.628 USD

Spread / Average Target

+180.13%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ABSCI CORPORATION	-26.67%	345M
LONZA GROUP AG	+38.65%	39.1B
IQVIA HOLDINGS INC.	-8.62%	38.76B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	31.24B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.9B
CELLTRION, INC.	-13.50%	25.8B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.06B
MEDPACE HOLDINGS, INC.	+34.36%	13.12B
BIO-TECHNE CORPORATION	-7.14%	11.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.61%	10.68B

Other Biotechnology & Medical Research